Patents by Inventor Abhijeet Jakate

Abhijeet Jakate has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240366575
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Application
    Filed: July 18, 2024
    Publication date: November 7, 2024
    Inventors: Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan, Mary Ann Johnson, Leonardo R. Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, JR., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • Publication number: 20240299369
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Application
    Filed: May 13, 2024
    Publication date: September 12, 2024
    Inventors: Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan, Mary Ann Johnson, Leonardo Resende Allain, W. Mark Eickhoff, Craig B. Ikeda, Chad D. Brown, Francis J. Flanagan, JR., Rebecca Nofsinger, Melanie Marota, Lisa Lupton, Paresh B. Patel, Hanmi Xi, Wei Xu
  • Patent number: 12070450
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Grant
    Filed: November 29, 2023
    Date of Patent: August 27, 2024
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan
  • Publication number: 20240245662
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Application
    Filed: March 1, 2024
    Publication date: July 25, 2024
    Inventors: Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan
  • Publication number: 20240180883
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Application
    Filed: February 13, 2024
    Publication date: June 6, 2024
    Inventors: Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan
  • Publication number: 20240100029
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Application
    Filed: November 29, 2023
    Publication date: March 28, 2024
    Inventors: Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan
  • Patent number: 11857542
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Grant
    Filed: June 16, 2023
    Date of Patent: January 2, 2024
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan
  • Publication number: 20230330072
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Application
    Filed: June 16, 2023
    Publication date: October 19, 2023
    Inventors: Joel M. Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan
  • Patent number: 11717515
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: August 8, 2023
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Joel Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan
  • Publication number: 20220340650
    Abstract: Disclosed are methods for treating headache, migraine and related symptoms by administering a long acting calcitonin gene related peptide (CGRP) antagonist and a short acting CGRP antagonist. Specifically, the disclosure provides a method for treating, preventing, alleviating, or reducing the frequency of occurrence of headache in a patient in need thereof, comprising administering to the patient: (a) a first calcitonin gene related peptide antagonist (CGRP antagonist) and (b) a second CGRP-antagonist, wherein the first CGRP antagonist is an antibody, and the second CGRP antagonist has a plasma half-life in humans of at most about 60 hours.
    Type: Application
    Filed: September 25, 2020
    Publication date: October 27, 2022
    Inventors: Abhijeet Jakate, Antonia Periclou, Ramesh Boinpally
  • Publication number: 20220193051
    Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 23, 2022
    Inventors: Joel Trugman, Ramesh Boinpally, Abhijeet Jakate, Michelle Finnegan